Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial.

ABSTRACT:

Rationale

Pulmonary coagulopathy may play a pathogenetic role in acute respiratory distress syndrome (ARDS), by contributing to alveolocapillary inflammation and increased permeability. Recombinant human activated protein C (rh-APC) may inhibit this process and thereby improve patient outcome.

Methods

A prospective randomized, saline-controlled, single-blinded clinical trial was performed in the intensive care units of two university hospitals, and patients with ARDS were included within 24 h after meeting inclusion criteria.

Intervention

A 4-day course of intravenous rh-APC (24 mcg/kg/h) (n = 33) versus saline (n = 38).

Outcomes

The primary outcome parameter was the pulmonary leak index (PLI) of 67Gallium-transferrin as a measure of alveolocapillary permeabili

SUBMITTER: Cornet AD 

PROVIDER: S-EPMC3954619 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature